Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel Swisher Insider Profile
11 Followers
Daniel Swisher, President & CEO, Director at Viracta Therapeutics, holds 0.00 shares in Corcept Therapeutics (Ticker: CORT), holds 104.55K shares in Cerus (Ticker: CERS), holds 55.01K shares in Jazz Pharmaceuticals (Ticker: JAZZ).
Daniel Swisher Viracta Therapeutics (VIRX)President & CEO, Director
Viracta Therapeutics (VIRX)
President & CEO, Director
Ranked #57,179 out of 98,564 Corporate Insiders
Profitable Transactions
4 out of 9 Profitable Transactions
Average Return
-2.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Daniel Swisher holds in companies
Most Profitable Insider Trade
The most profitable trade made by Daniel Swisher
Daniel Swisher's Trading History
Viracta Therapeutics
Mar 02, 2016
President & CEO, Director
Uninformative Buy
―
$321.22K
Jazz Pharmaceuticals
Mar 07, 2023
President & COO
Uninformative Buy
―
$6.03M
Protagonist Therapeutics
―
Director
―
―
Cerus
Jun 09, 2023
Director
Uninformative Buy
200.00K
$175.64K
Corcept Therapeutics
Apr 03, 2024
Director
Uninformative Sell
55.66K
$0.00
List of latest transactions for each holding click on a transaction to see Daniel Swisher's performance on stock
You May Also Like
Daniel Swisher insider profile FAQ
What is the percentage of profitable transactions made by Daniel Swisher?
The percentage of profitable transactions made by Daniel Swisher is 44%.
What is the average return per transaction made by Daniel Swisher?
The average return per transaction made by Daniel Swisher is -2.90%.
What stocks does Daniel Swisher hold?
Daniel Swisher holds: VIRX, JAZZ, PTGX, CERS, CORT stocks.
What was Daniel Swisher’s latest transaction?
Daniel Swisher latest transaction was an Uninformative Sell of $55.66K.
What was Daniel Swisher's most profitable transaction?
Daniel Swisher’s most profitable transaction was an Informative Sell of CERS stock on November 14, 2022. The return on the trade was 47.40%.
What is Daniel Swisher's role in Viracta Therapeutics?
Daniel Swisher's role in Viracta Therapeutics is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.